Caxton Associates LP Has $739,000 Stock Position in Amgen Inc. (NASDAQ:AMGN)

Caxton Associates LP decreased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 82.1% during the 2nd quarter, Holdings Channel reports. The firm owned 2,364 shares of the medical research company’s stock after selling 10,822 shares during the period. Caxton Associates LP’s holdings in Amgen were worth $739,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Grassi Investment Management acquired a new position in shares of Amgen during the 1st quarter worth approximately $2,283,000. Public Employees Retirement System of Ohio increased its holdings in shares of Amgen by 1.6% during the 4th quarter. Public Employees Retirement System of Ohio now owns 281,791 shares of the medical research company’s stock worth $81,161,000 after acquiring an additional 4,376 shares during the last quarter. Meyer Handelman Co. increased its holdings in shares of Amgen by 7.2% during the 2nd quarter. Meyer Handelman Co. now owns 129,831 shares of the medical research company’s stock worth $40,566,000 after acquiring an additional 8,700 shares during the last quarter. Chicago Partners Investment Group LLC increased its holdings in shares of Amgen by 1.3% during the 4th quarter. Chicago Partners Investment Group LLC now owns 4,543 shares of the medical research company’s stock worth $1,388,000 after acquiring an additional 57 shares during the last quarter. Finally, Novak & Powell Financial Services Inc. acquired a new position in shares of Amgen during the 4th quarter worth approximately $803,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Price Performance

Amgen stock opened at $319.10 on Friday. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.89 and a current ratio of 1.26. Amgen Inc. has a 52 week low of $249.70 and a 52 week high of $346.85. The stock has a market capitalization of $171.18 billion, a P/E ratio of 45.52, a price-to-earnings-growth ratio of 2.98 and a beta of 0.61. The stock has a fifty day moving average of $329.18 and a 200-day moving average of $306.91.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a return on equity of 161.72% and a net margin of 10.12%. The business had revenue of $8.39 billion for the quarter, compared to analyst estimates of $8.35 billion. During the same period last year, the firm posted $5.00 EPS. Amgen’s quarterly revenue was up 20.1% on a year-over-year basis. On average, sell-side analysts expect that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Stockholders of record on Friday, August 16th were issued a dividend of $2.25 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.82%. Amgen’s dividend payout ratio (DPR) is currently 128.57%.

Analysts Set New Price Targets

A number of research analysts recently weighed in on AMGN shares. Wells Fargo & Company lowered Amgen from an “overweight” rating to an “equal weight” rating and boosted their target price for the stock from $320.00 to $335.00 in a report on Wednesday, August 7th. Royal Bank of Canada reissued an “outperform” rating and set a $362.00 target price on shares of Amgen in a report on Thursday. Argus boosted their target price on Amgen from $300.00 to $340.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Jefferies Financial Group reissued a “buy” rating and set a $380.00 target price (up from $375.00) on shares of Amgen in a report on Wednesday, August 7th. Finally, Robert W. Baird reissued an “underperform” rating and set a $215.00 target price on shares of Amgen in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $321.37.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.